⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9839360 | 0.53 | — | — | |
| SCHEMBL9384920 | 0.50 | — | — | |
| SCHEMBL3188857 | 0.50 | — | — | |
| SCHEMBL442655 | 0.41 | — | — | |
| SCHEMBL26660960 | 0.25 | — | — | |
| SCHEMBL25434707 | 0.20 | — | — | |
| SCHEMBL5134016 | 0.20 | — | — | |
| SCHEMBL6559802 | 0.20 | — | — | |
| SCHEMBL11498741 | 0.20 | — | — | |
| SCHEMBL157229 | 0.20 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896730-B2 | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment | OSI Pharmaceuticals, LLC (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2702173-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | OSI Pharmaceuticals, LLC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057352-A1 | METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL-LIKE TUMOR CELLS OR THEIR FORMATION | OSI PHARMACEUTICALS LLC (US) | 2014-02-27 | — | — | US | disclosed |
| US-8642834-B2 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | OSI Pharmaceuticals, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2013152252-A1 | COMBINATION ANTI-CANCER THERAPY | OSI Pharmaceuticals, LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130210026-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI Pharmaceuticals, LLC | 2013-08-15 | — | — | US | disclosed |
| US-8465912-B2 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | OSI Pharmaceuticals, LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-8377636-B2 | Biological markers predictive of anti-cancer response to kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120302572-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | AVEO PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012149014-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | OSI Pharmaceuticals, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-1565475-B1 | DIAZINOPYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009009016-A1 | COMBINATION ANTI-CANCER THERAPY | OSI PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008992-A2 | COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 | OSI PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080312260-A1 | Biological markers predictive of anti-cancer response to kinase inhibitors | HALEY JOHN D | 2008-12-18 | — | — | US | disclosed |
| WO-2008127719-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20050261284-A1 | Diazinopyrimidines | CHEN JIAN J | 2005-11-24 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1565475-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046152-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN LA ROCHE AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |